NEW YORK (GenomeWeb News) – XDx today announced a deal with Laboratory Corporation of America to develop and commercialize a diagnostic test for systemic lupus erythematosus (SLE).

The two firms will work together in the discovery phase while LabCorp will develop and commercialize a test to predict flares of lupus. The collaboration pairs XDx's autoimmune diagnostics research and discovery expertise as well as SLE blood sample database with LabCorp's diagnostic development and commercialization resources, they said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.